The mechanism of action for the compound 32 as an anticancer was explained by suppressing ovarian tumor growth through inhibition of monocyte chemoattractant protein-1 (MCP-1), regulated upon activation, normal T cell expressed and secreted (RANTES), and vascular endothelial growth factor (VEGF) expressions [38]. This evidence concerns the gene CCL2 and ovarian neoplasm.